OptiBiotix Health plc
("OptiBiotix" or the "Company" or "the Group")
Directorate change
OptiBiotix Health plc ("OptiBiotix") announces that Graham Myers, Finance Director of the Company, has notified the Company that he will step down from the Board on 30 November 2024.
David Blain will join the Company as acting Finance Director on 1 November 2024. Mr Blain's appointment to the Board of the Company will be subject to normal regulatory due diligence.
David is a member of ICAEW and has extensive financial, commercial and Board experience in a number of private and public companies, including Iksuda Therapeutics Ltd, Applied Graphene Materials plc, Nanoco Group plc and Inspired Capital plc (formerly Renovo Group plc). Mr Blain is currently Financial Director (non-board position) at Iksuda Therapeutics Ltd.
The Company notes recent speculation in relation to the health of the Company's Chief Executive Officer Stephen O'Hara. Mr O'Hara is recovering after a short illness and expects to be back at work shortly.
Neil Davidson, Chairman of OptiBiotix Health plc said: "On behalf of the Board, I would like to thank Graham for his contribution to the Company over the last year and welcome David as we move to our next stage of growth."
| For further information, please contact: OptiBiotix Health plc | ||
| Neil Davidson, Chairman | Contact via Walbrook below | |
| Stephen O'Hara, Chief Executive | | |
|
| | |
| Cairn Financial Advisers LLP (NOMAD) | Tel: 020 7213 0880 | |
| Liam Murray / Jo Turner / Ludovico Lazzaretti | | |
|
| | |
| Peterhouse Capital Limited (Broker) | Tel: 020 7220 9797 | |
| Duncan Vasey / Lucy Williams | | |
| | | |
| Walbrook PR Ltd | Mob: 07876 741 001 | |
| Anna Dunphy | | |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
